Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.11.6351

The Kampo Medicine Goshajinkigan Prevents Neuropathy in Breast Cancer Patients Treated with Docetaxel  

Abe, Hajime (Breast Center, Bell Land General Hospital)
Kawai, Yuki (Division of Breast and General Surgery, Shiga University of Medical Science Hospital)
Mori, Tsuyoshi (Division of Breast and General Surgery, Shiga University of Medical Science Hospital)
Tomida, Kaori (Division of Breast and General Surgery, Shiga University of Medical Science Hospital)
Kubota, Yoshihiro (Division of Breast and General Surgery, Shiga University of Medical Science Hospital)
Umeda, Tomoko (Division of Breast and General Surgery, Shiga University of Medical Science Hospital)
Tani, Tohru (Department of Surgery, Shiga University of Medical Science)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.11, 2013 , pp. 6351-6356 More about this Journal
Abstract
Background: Goshajinkigan (GJG) is used for the treatment of several neurological symptoms. We investigated the efficacy of GJG and mecobalamin (B12) against neurotoxicity associated with docetaxel (DOC) in breast cancer patients. Materials and Methods: Sixty breast cancer patients were treated with DOC. Thirty-three patients (GJG group) received oral administration of 7.5 g/day GJG and 27 patients (B12 group) received oral administration of 1500 ${\mu}g/day$ B12. Neuropathy was evaluated according to DEB-NTC (Neurotoxicity Criteria of Debiopharm), Common Terminology Criteria for Adverse Events (NCI-CTC) ver. 3.0, and a visual analogue scale (VAS). This study employed a randomized open design. Results: The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01). In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases. Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases, and VAS was $2.7{\pm}2.2$. In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively; and grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case, and VAS was $4.9{\pm}2.4$. Conclusions: Concomitant administration of GJG is useful in preventing neuropathy in breast cancer patients treated with a DOC regimen.
Keywords
Breast cancer; goshajinkigan; docetaxel; peripheral neuropathy; mecobalamin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Argyriou AA, Koltzenburg M, Polychronopoulos P, et al (2008). Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol, 66, 218-28.   DOI   ScienceOn
2 Calhoun EA, Welshman EE, Chang CH, et al (2003). Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer, 13, 741-8.   DOI   ScienceOn
3 Carlson K, Ocean AJ (2011). Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer, 11, 73-81.   DOI   ScienceOn
4 De Laurentiis M, Cancello G, D’Agostino D, et al (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 26, 44-53.   DOI   ScienceOn
5 Postma TJ, Aaronson NK, Heimans JJ, et al (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer, 41, 1135-9.   DOI   ScienceOn
6 Rao RD, Flynn PJ, Sloan JA, et al (2008). Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 112, 2802-8.   DOI   ScienceOn
7 Ravdin PM, Burris HA 3rd, Cook G, et al (1995). Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol, 13, 2879-85.   DOI
8 Roche H, Fumoleau P, Spielmann M, et al (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol, 24, 5664-71.   DOI   ScienceOn
9 Smith TJ, Staats PS, Deer T, et al (2002). Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol, 20, 4040-9.   DOI   ScienceOn
10 Sparano JA, Wang M, Martino S, et al (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 358, 1663-71.   DOI   ScienceOn
11 Stubblefield MD, Burstein HJ, Burton AW, et al (2009). NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw, 7, 1-26.   DOI
12 Swain SM, Arezzo JC (2008). Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol, 6, 455-67.
13 Henderson IC, Berry DA, Demetri GD, et al (2003). Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21, 976-83.   DOI   ScienceOn
14 Gilron I, Bailey JM, Tu D, et al (2005). Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med, 352, 1324-34.   DOI   ScienceOn
15 Gotoh A, Goto K, Sengoku A, et al (2004). Inhibition mechanism of Gosha-jinki-gan on the micturition reflex in rats. J Pharmacol Sci, 96, 115-23.   DOI   ScienceOn
16 Hausheer FH, Schilsky RL, Bain S, et al (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol, 33, 15-49.
17 Hu X, Sato J, Oshida Y, et al (2003). Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract, 59, 103-11.   DOI   ScienceOn
18 Huskisson EC (1974). Measurement of pain. Lancet, 2, 1127-31.
19 Imamura T, Ishizuka O, Aizawa N, et al (2008). Gosha-jinki-gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder. Neurourol Urodyn, 27, 832-7.   DOI   ScienceOn
20 Inoue N, Ishida H, Sano M, et al (2011). Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol, 17, 341-7.
21 Jones SE, Erban J, Overmoyer B, et al (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol, 23, 5542-51.   DOI   ScienceOn
22 Yamada K, Suzuki E, Nakaki T, et al (2005). Aconiti tuber increases plasma nitrite and nitrate levels in humans. J Ethnopharmacol, 96, 165-9.   DOI   ScienceOn
23 Takemoto S, Ushijima K, Honda K, et al (2012). Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy. Int J Clin Oncol, 17, 367-72.   DOI   ScienceOn
24 Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81.   DOI   ScienceOn
25 Uno T, Ohsawa I, Tokudome M, et al (2005). Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetes. Diabetes Res Clin Pract, 69, 129-35.   DOI   ScienceOn
26 Lee JJ, Swain SM (2006). Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol, 24, 1633-42.   DOI   ScienceOn
27 Katsumata N, Noda K, Nozawa S, et al (2005). Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer, 93, 999-1004.   DOI   ScienceOn
28 Kono T, Mamiya N, Chisato N, et al (2011). Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med, 2011, 418481..
29 Kuwabara S, Nakazawa R, Azuma N, et al (1999). Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med, 38, 472-5.   DOI
30 Muro K, Hamaguchi T, Ohtsu A, et al (2004). A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol, 15, 955-9.   DOI   ScienceOn
31 Nagaki Y, Hayasaka S, Hayasaka Y, et al (2003). Effects of goshajinkigan on corneal sensitivity, superficial punctate keratopathy and tear secretion in patients with insulin-dependent diabetes mellitus. Am J Chin Med, 31, 103-9.   DOI   ScienceOn
32 Naito S, Tsukamoto T, Koga H, et al (2008). Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol, 38, 365-72   DOI   ScienceOn
33 Nishioka M, Shimada M, Kurita N, et al (2011). The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol, 16, 322-7.   DOI